Physician profile
Muhammad Farhan
NPI 1962748541
$12,533.53
in general payments reported to CMS, 2019-2025
54 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $729 · 2021: $1,256 · 2022: $3,591 · 2023: $2,481 · 2024: $2,689 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,079 · Education: $77.98 · Entertainment: $15.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,079.36 |
| Education | $77.98 |
| Entertainment | $15.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,626.39 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $1,386.96 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Abbvie INC. | $1,015.11 | 2021-2025 | |
| Amgen INC. | $918.49 | 2019-2025 | Tavneos, Krystexxa, Otezla |
| Glaxosmithkline, LLC. | $750.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $717.56 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $697.49 | 2019-2025 | Jynarque, Rexulti |
| Pfizer INC. | $587.21 | 2019-2024 | |
| Lilly USA, LLC | $510.96 | 2019-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $381.61 | 2019-2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $343.12 | 2022-2025 | Tarpeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.57 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Merck Sharp & Dohme LLC | $310.94 | 2019-2025 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $270.70 | 2020-2025 | |
| Horizon Therapeutics Plc | $222.01 | 2022-2023 | Krystexxa |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $207.58 | 2023-2025 | |
| Vifor Pharma, INC. | $205.46 | 2019-2025 | Veltassa, Korsuva |
| Inogen, INC. | $203.03 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen At Home Stationary Concentrator |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.19 | 2022-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $164.00 | 2022-2024 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $147.98 | 2022-2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $117.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.54 | 2022-2024 | Glassia, Aralast |
| Ardelyx, INC. | $94.82 | 2024-2025 | Ibsrela |
| Nxstage Medical, INC. | $89.93 | 2019-2023 | Liberty Select Cycler |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.86 | 2022-2024 | Caplyta |
| Opko Pharmaceuticals, LLC | $65.58 | 2025 | Rayaldee |
| Lundbeck LLC | $65.36 | 2023 | Vyepti, Rexulti |
| Nestle Healthcare Nutrition INC. | $57.65 | 2023 | |
| Alnylam Pharmaceuticals INC. | $52.88 | 2022-2023 | Oxlumo |
| Phathom Pharmaceuticals, INC. | $52.86 | 2024-2025 | Voquezna |
| Shire North American Group INC | $52.64 | 2019 | |
| Aurinia Pharma U.S., INC. | $49.05 | 2022-2023 | Lupkynis |
| Insulet Corporation | $46.58 | 2023 | Omnipod |
| Allergan, INC. | $37.82 | 2019-2020 | |
| Kyowa Kirin, INC. | $34.15 | 2024 | Crysvita |
| Medtronic Minimed, INC. | $25.34 | 2020 | |
| Fresenius USA Marketing, INC. | $25.11 | 2025 | Velphoro |
| Tandem Diabetes Care, INC. | $24.28 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Grifols USA, LLC | $24.05 | 2019 | |
| Verona Pharma, INC. | $21.62 | 2025 | Ohtuvayre |
| Radius Health, INC. | $20.12 | 2024 | Tymlos |
| Aimmune Therapeutics, INC. | $19.32 | 2024 | |
| Bausch Health US, LLC | $18.43 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.98 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.80 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.96 | 2021 | |
| Atricure, INC. | $15.78 | 2024 | |
| Optos, INC. | $15.64 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Abbott Laboratories | $15.12 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2023 | Camzyos |
| Mallinckrodt Hospital Products INC. | $13.71 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.31 | 2024 | Rebyota |
| Smith+Nephew, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Farhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.